IMR Press / RCM / Volume 16 / Issue 2 / DOI: 10.3909/ricm0762
Open Access Review
Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial
Show Less
1 Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA
2 Jonathan and Karin Fielding School of Public Health at UCLA, Los Angeles, CA
3 UCLA Barbra Streisand Women's Heart Health Program, Los Angeles, CA
Rev. Cardiovasc. Med. 2015 , 16(2), 125–130;
Published: 30 June 2015
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality in developed countries. The management of blood cholesterol through use of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) in at-risk patients is a pillar of medical therapy for the primary and secondary prevention of cardiovascular disease. The recent 2013 American College of Cardiology/American Heart Association guideline on managing blood cholesterol provides an important framework for the effective implementation of risk-reduction strategies. The guideline identifies four cohorts of patients with proven benefits from statin therapy and streamlines the dosing and monitoring recommendations based on evidence from published, randomized controlled trials. Primary care physicians and cardiologists play key roles in identifying populations at elevated ASCVD risk. In providing a practical management overview of the current blood cholesterol guideline, we facilitate more informed discussions on treatment options between healthcare providers and their patients.
Atherosclerotic cardiovascular disease
Low-density lipoprotein cholesterol
High-density lipoprotein cholesterol
Risk reduction
Statin drugs
Back to top